PEDS-03: Spina Bifida and Neural Tube Defects — Part 1 (Part 1 of 2)

Section 1: Embryology, Epidemiology, and Folate Prevention

PEDS-03-a · ~04:00

Bottom line: the neural tube closes by day 28 post-conception (anterior neuropore day 25, posterior neuropore day 27 to 28), often before a woman knows she is pregnant. Folic acid supplementation must therefore begin preconceptionally: 0.4 mg daily for all women of childbearing age, 4 mg daily for women with a prior NTD-affected pregnancy. United States mandatory grain fortification (1998) reduced NTD prevalence by approximately 26 to 28 percent. Valproic acid is the most teratogenic commonly used antiepileptic drug (10 to 20x baseline risk).

The neural tube forms by fusion of the neural folds during the third and fourth weeks of embryonic development. The anterior neuropore closes by day 25 post-conception and the posterior neuropore by day 27 to 28. Failure of posterior neuropore closure produces myelomeningocele; failure of anterior closure produces anencephaly. Because the entire process is complete before the first missed menstrual period, prevention must begin preconceptionally at the population level. This is a fixed biological constraint, not a behavioral one. A woman who learns she is pregnant at 6 weeks and immediately starts folic acid has missed the window by a full month.

Epidemiology. United States NTD prevalence is approximately 0.5 to 0.7 per 1000 live births, down from approximately 1.0 to 1.5 per 1000 before mandatory folic acid grain fortification began in 1998. Worldwide prevalence ranges from 0.5 to 2.0 per 1000 by region, ethnicity, and dietary practice. Myelomeningocele accounts for approximately 90 percent of live-born NTDs that require postnatal treatment. Anencephaly is the other major contributor but is incompatible with life and so is rarely seen on rehabilitation wards. Sex distribution is roughly equal, with a slight female predominance.

Folate prevention: the evidence base. The Medical Research Council Vitamin Study (Lancet 1991) was a randomized controlled trial demonstrating a 72 percent reduction in NTD recurrence with 4 mg folic acid daily in women with a prior NTD pregnancy. Czeizel and Dudas (NEJM 1992) extended that finding by demonstrating that folic acid prevents first-occurrence NTDs as well. Together these two trials established the dosing standard. The recommended doses are 0.4 mg (400 mcg) daily for all women of childbearing age (ongoing, preconceptional, lifelong) and 4 mg daily for women with a prior NTD-affected pregnancy (start 1 to 3 months before conception and continue through the first trimester). United States mandatory grain fortification since 1998 has reduced NTD prevalence by approximately 26 to 28 percent in the general population, a smaller relative effect than the 72 percent seen in supplemented high-risk individuals because dietary intake from fortification is modest.

Risk factors for NTDs. Prior NTD-affected pregnancy carries a recurrence risk of 2 to 5 percent (10 to 20-fold the population baseline); two affected siblings push the risk to approximately 10 percent. Other major risk factors include maternal folate deficiency (the primary modifiable risk factor), maternal diabetes (2 to 10x baseline), maternal obesity (1.5 to 3.5x baseline), maternal first-trimester hyperthermia (febrile illness or hot tub exposure), and several teratogenic medications. Valproic acid carries a 1 to 2 percent NTD risk (10 to 20x baseline) and is the most teratogenic commonly used antiepileptic drug. Carbamazepine carries a 0.5 to 1 percent risk. Folic acid antagonists (methotrexate, trimethoprim, aminopterin) also raise risk. Hispanic ethnicity and lower socioeconomic status are independent epidemiologic associations, likely mediated by dietary folate intake and access to prenatal care.

The clinical implication for the rehabilitation physician is direct: any woman of childbearing age on valproic acid for spasticity, headache, or seizure deserves explicit preconceptional counseling, a 4 mg folic acid prescription if she might become pregnant, and frank discussion of switching to a less teratogenic agent (lamotrigine or levetiracetam) when feasible. This conversation belongs in the rehabilitation clinic, not just the obstetrician’s office.

Why fortification works. Mandatory grain fortification (140 mcg folic acid per 100 g of enriched cereal grain in the United States since January 1998) operates as a population-level intervention precisely because it bypasses the behavioral problem. A woman who plans a pregnancy and takes prenatal vitamins is already in the lowest-risk group; the women who benefit most from fortification are those whose pregnancies are unplanned or who first present for care after the neuropore has already closed. The 26 to 28 percent reduction is the residual benefit captured even when no intentional supplementation occurs, and it has been replicated in dozens of countries that have adopted similar fortification policies. Conversely, countries without fortification continue to see NTD rates 2 to 3 times higher than the United States.